The Effects of Wheat Sprouts Supplements on the Key Health Indicators of the Patients With Breast Cancer After Chemotherapy

To explore the effects of wheat sprouts supplements on the key health indicators of the patients with breast cancer after chemotherapy, Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy and nutritional status, immune function, quality of life were measured and evaluated. Through data analysis, we found that Maiji tablets may improve the symptoms of appetite loss, nausea and vomiting, and fatigue in patients with breast cancer during chemotherapy. Meanwhile it may help patients maintain weight, keep appetite and improve the food intake.

Study Overview

• Status: Completed
• Conditions: Nutritional Status, Immune Function, Quality of Life Uring the Progress of Chemotherapy
• Intervention / Treatment: Dietary supplement: wheat sprouts supplement

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310009
      • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

patients diagnosed with breast cancer, receiving chemotherapy for the first time

Description

Inclusion Criteria:

- patients diagnosed with breast cancer, receiving chemotherapy for the first time

Exclusion Criteria:

- Patients with severe liver or kidney disease or other infectious diseases

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
quality of life	Quality of life was measured by quality of life assessment form	28 days
weight	the weight of patients	28 days
nutritional status	nutritional status of patients	28 days

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: Zhejiang Cancer Hospital; Beijing Shijitan Hospital, Capital Medical University; Jinhua Municipal Central Hospital; First Affiliated Hospital of Wenzhou Medical University; Quzhou Kecheng People's Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2019
• Primary Completion (Actual): August 22, 2020
• Study Completion (Actual): October 1, 2020

Study Registration Dates

• First Submitted: August 3, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 10, 2021

Study Record Updates

• Last Update Posted (Actual): August 10, 2021
• Last Update Submitted That Met QC Criteria: August 3, 2021
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: 2018-172

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No